https://www.live-feeds.com/feed/novartis-ionis-experimental-heart-drug-misses-key-goal-in-closely-watched-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-ionis-experimental-heart-drug-misses-key-goal-in-closely-watched-trialhttps://www.live-feeds.com/feed/novartis-ionis-experimental-heart-drug-misses-key-goal-in-closely-watched-trial#u62143Wed, 09 Sep 2026 02:12:01 +0000Novartis and Ionis Pharmaceuticals experimental heart drug pelacarsen failed its primary endpoint in a Phase 3 trial. While the therapy lowered Lp(a) protein levels in over 8,000 patients, it failed to reduce cardiovascular deaths, strokes, or heart attacks. Ionis Pharmaceuticals shares dropped 13.1% to $50, while Novartis shares fell more than three percent on Monday. The result creates pipeline challenges for Novartis and increases pressure on CEO Vas Narasimhan regarding the company's acquisition strategy and overall pipeline.Why it mattersPelacarsen was viewed as a potential blockbust https://www.live-feeds.com/feed/novartis-ionis-experimental-heart-drug-misses-key-goal-in-closely-watched-trialhttps://www.live-feeds.com/feed/novartis-ionis-experimental-heart-drug-misses-key-goal-in-closely-watched-trial#u61173Tue, 08 Sep 2026 08:00:38 +0000Novartis and Ionis Pharmaceuticals face investor pressure after their experimental cardiovascular therapy, pelacarsen, missed its primary endpoint in a late-stage trial. Although the treatment successfully reduced levels of a protein particle known as Lp(a), the study did not demonstrate a significant reduction in cardiovascular events. The setback triggered a drop in Novartis shares of more than three percent on Monday. The failure deals a blow to expectations for the drug as a potential blockbuster treatment and heightens pressure on upcoming data from a muscle-wasting therapy.Why it matters https://www.live-feeds.com/feed/novartis-ionis-experimental-heart-drug-misses-key-goal-in-closely-watched-trialhttps://www.live-feeds.com/feed/novartis-ionis-experimental-heart-drug-misses-key-goal-in-closely-watched-trial#u58723Sun, 06 Sep 2026 03:37:01 +0000Novartis and Ionis Pharmaceuticals' experimental heart drug, pelacarsen, failed to meet its primary goal in a closely watched late-stage trial. The drug aimed to lower cardiovascular risk by reducing levels of a protein particle called Lp(a). Despite achieving this, the trial did not show a significant reduction in cardiovascular events. This development has significant implications for cardiovascular drug research.Why it mattersThe failure of pelacarsen is a setback for Novartis and Ionis, as well as for the emerging class of heart medicines targeting Lp(a). Cardiovascular disease remain